{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:45:00Z","timestamp":1786463100927,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13760-026-03063-3","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:48:47Z","timestamp":1776095327000},"page":"1259-1268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond relapse control: motor and cognitive subclinical progression in RRMS \u2014a real-world longitudinal study of ocrelizumab and interferon beta"],"prefix":"10.1007","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8250-7635","authenticated-orcid":false,"given":"Stefan","family":"Todorovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9852-0308","authenticated-orcid":false,"given":"Slobodan","family":"Vojinovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2299-3512","authenticated-orcid":false,"given":"Dejan","family":"Savi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3299-5404","authenticated-orcid":false,"given":"Milo\u0161","family":"Danilovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1857-4216","authenticated-orcid":false,"given":"Dejan","family":"Aleksi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"2","key":"3063_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378(2):169\u2013180. https:\/\/doi.org\/10.1056\/NEJMra1401483","journal-title":"N Engl J Med"},{"issue":"4","key":"3063_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, Kubala Havrdova E, Spelman T, Izquierdo G, Eichau S, Trojano M, Lugaresi A, Hupperts R, Sola P, Ferraro D, Lycke J, Grand\u2019Maison F, Prat A, Girard M, Duquette P, Larochelle C, Svenningsson A, Petersen T, Grammond P, Granella F, Van Pesch V, Bergamaschi R, McGuigan C, Coles A, Hillert J, Piehl F, Butzkueven H, Kalincik T (2020) MSBase study group. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19(4):307\u2013316. https:\/\/doi.org\/10.1016\/S1474-4422(20)30067-3","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"3063_CR3","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","volume":"9","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A, Vollmer T (2016) Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord 9(Suppl 1):S5\u2013S48. https:\/\/doi.org\/10.1016\/j.msard.2016.07.003","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"3063_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand\u2019Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N (2019) MSBase Study Group. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA 321(2):175\u2013187. https:\/\/doi.org\/10.1001\/jama.2018.20588","journal-title":"JAMA"},{"issue":"2","key":"3063_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","volume":"72","author":"DL Rotstein","year":"2015","unstructured":"Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL (2015) Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 72(2):152\u2013158. https:\/\/doi.org\/10.1001\/jamaneurol.2014.3537","journal-title":"JAMA Neurol"},{"issue":"5","key":"3063_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"MS-EPIC San Francisco","year":"2019","unstructured":"University of California, San Francisco MS-EPIC, Team; Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, Bischof A, Gundel T, Zhu AH, Papinutto N, Stern WA, Bevan C, Romeo A, Goodin DS, Gelfand JM, Graves J, Green AJ, Wilson MR, Zamvil SS, Zhao C, Gomez R, Ragan NR, Rush GQ, Barba P, Santaniello A, Baranzini SE, Oksenberg JR, Henry RG, Hauser SL (2019) Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 85(5):653\u2013666. https:\/\/doi.org\/10.1002\/ana.25463","journal-title":"Ann Neurol"},{"key":"3063_CR7","doi-asserted-by":"publisher","first-page":"106529","DOI":"10.1016\/j.msard.2025.106529","volume":"100","author":"MA Z\u00e1rate","year":"2025","unstructured":"Z\u00e1rate MA, Marrodan M, Piedrabuena MA, Fiol MP, Ysrraelit MC, Correale J (2025) Development of early progression independent of relapse activity significantly impacts on disability accumulation in patients with multiple sclerosis. Mult Scler Relat Disord 100:106529. https:\/\/doi.org\/10.1016\/j.msard.2025.106529","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"3063_CR8","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1007\/s00415-024-12448-4","volume":"271","author":"E Portaccio","year":"2024","unstructured":"Portaccio E, Betti M, De Meo E, Addazio I, Past\u00f2 L, Razzolini L, Totaro R, Spitaleri D, Lugaresi A, Cocco E, Onofrj M, Di Palma F, Patti F, Maimone D, Valentino P, Torri Clerici V, Protti A, Ferraro D, Lus G, Maniscalco GT, Brescia Morra V, Salemi G, Granella F, Pesci I, Bergamaschi R, Aguglia U, Vianello M, Simone M, Lepore V, Iaffaldano P, Comi G, Filippi M, Trojano M, Amato MP (2024) Italian Multiple Sclerosis Register. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression. J Neurol 271(8):5074\u20135082. https:\/\/doi.org\/10.1007\/s00415-024-12448-4","journal-title":"J Neurol"},{"issue":"10","key":"3063_CR9","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","volume":"19","author":"RHB Benedict","year":"2020","unstructured":"Benedict RHB, Amato MP, DeLuca J, Geurts JJG (2020) Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol 19(10):860\u2013871. https:\/\/doi.org\/10.1016\/S1474-4422(20)30277-5","journal-title":"Lancet Neurol"},{"issue":"6","key":"3063_CR10","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/1352458516645869","volume":"23","author":"SL Costa","year":"2017","unstructured":"Costa SL, Genova HM, DeLuca J, Chiaravalloti ND (2017) Information processing speed in multiple sclerosis: Past, present, and future. Mult Scler 23(6):772\u2013789. https:\/\/doi.org\/10.1177\/1352458516645869","journal-title":"Mult Scler"},{"issue":"6","key":"3063_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000004977","volume":"90","author":"JF Sumowski","year":"2018","unstructured":"Sumowski JF, Benedict R, Enzinger C, Filippi M, Geurts JJ, Hamalainen P, Hulst H, Inglese M, Leavitt VM, Rocca MA, Rosti-Otajarvi EM, Rao S (2018) Cognition in multiple sclerosis: State of the field and priorities for the future. Neurology 90(6):278\u2013288. https:\/\/doi.org\/10.1212\/WNL.0000000000004977","journal-title":"Neurology"},{"issue":"9","key":"3063_CR12","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/1352458517703193","volume":"23","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G, Tomic D, Bright JR, Havrdov\u00e1 E (2017) No evident disease activity: The use of combined assessments in the management of patients with multiple sclerosis. Mult Scler 23(9):1179\u20131187. https:\/\/doi.org\/10.1177\/1352458517703193","journal-title":"Mult Scler"},{"issue":"3","key":"3063_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L (2017) OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 376(3):221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"issue":"2","key":"3063_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"3063_CR15","unstructured":"Australian National COVID-19 Clinical Evidence Taskforce Australian guidelines for the clinical care of people with COVID-19, Version 16. Australian National COVID-19 Clinical Evidence Taskforce; 2020 [cited 2020 August 2]. Available from https:\/\/covid19evidence.net.au"},{"issue":"1","key":"3063_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00415-023-12021-1","volume":"271","author":"K Selmaj","year":"2024","unstructured":"Selmaj K, Cree BAC, Barnett M, Thompson A, Hartung HP (2024) Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol 271(1):105\u2013115. https:\/\/doi.org\/10.1007\/s00415-023-12021-1","journal-title":"J Neurol"},{"issue":"5","key":"3063_CR17","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s40120-023-00469-0","volume":"12","author":"CK Geiger","year":"2023","unstructured":"Geiger CK, Sheinson D, To TM, Jones D, Bonine NG (2023) Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab. Neurol Ther 12(5):1709\u20131728. https:\/\/doi.org\/10.1007\/s40120-023-00469-0","journal-title":"Neurol Ther"},{"key":"3063_CR18","doi-asserted-by":"publisher","unstructured":"Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A et al (2020) Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology. ; 95(14):e1999-e2008. https:\/\/doi.org\/10.1212\/WNL.0000000000010380","DOI":"10.1212\/WNL.0000000000010380"},{"issue":"Suppl 1","key":"3063_CR19","first-page":"S17","volume":"74","author":"S Dhib-Jalbut","year":"2010","unstructured":"Dhib-Jalbut S, Marks S (2010) Interferon-beta mechanisms of action in multiple sclerosis. Neurology 74(Suppl 1):S17\u201324","journal-title":"Neurology"},{"issue":"Suppl 1","key":"3063_CR20","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.clineuro.2013.09.024","volume":"115","author":"J Drulovic","year":"2013","unstructured":"Drulovic J, Kostic J, Mesaros S, Dujmovic Basuroski I, Stojsavljevic N, Kisic-Tepavcevic D et al (2013) Interferon-beta and disability progression in relapsing-remitting multiple sclerosis. Clin Neurol Neurosurg 115(Suppl 1):S65\u2013S69","journal-title":"Clin Neurol Neurosurg"},{"issue":"10076","key":"3063_CR21","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(16)31320-4","volume":"389","author":"D Ontaneda","year":"2017","unstructured":"Ontaneda D, Thompson AJ, Fox RJ, Cohen JA (2017) Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet 389(10076):1357\u20131366. https:\/\/doi.org\/10.1016\/S0140-6736(16)31320-4","journal-title":"Lancet"},{"issue":"13","key":"3063_CR22","doi-asserted-by":"publisher","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","volume":"95","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Kappos L, Arnold DL, Bar-Or A, Brochet B, Naismith RT et al (2020) Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology 95(13):e1854\u2013e1867. https:\/\/doi.org\/10.1212\/WNL.0000000000010376","journal-title":"Neurology"},{"key":"3063_CR23","doi-asserted-by":"publisher","first-page":"105570","DOI":"10.1016\/j.msard.2024.105570","volume":"86","author":"L Diem","year":"2024","unstructured":"Diem L, Ovchinnikov A, Friedli C, Hammer H, Kamber N, Chan A et al (2024) Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers. Mult Scler Relat Disord 86:105570. https:\/\/doi.org\/10.1016\/j.msard.2024.105570","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"3063_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","volume":"4","author":"G Giovannoni","year":"2015","unstructured":"Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M (2015) Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 4(4):329\u2013333. https:\/\/doi.org\/10.1016\/j.msard.2015.04.006","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"3063_CR25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1001\/jamaneurol.2020.4891","volume":"78","author":"E De Meo","year":"2021","unstructured":"De Meo E, Portaccio E, Giorgio A, Ruano L, Goretti B, Niccolai C et al (2021) Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. JAMA Neurol 78(4):414\u2013425. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4891","journal-title":"JAMA Neurol"},{"key":"3063_CR26","doi-asserted-by":"publisher","first-page":"104952","DOI":"10.1016\/j.msard.2023.10495229","volume":"79","author":"J Lechner-Scott","year":"2023","unstructured":"Lechner-Scott J, Agland S, Allan M, Darby D, Diamond K, Merlo D, van der Walt A (2023) Managing cognitive impairment and its impact in multiple sclerosis: An Australian multidisciplinary perspective. Mult Scler Relat Disord 79:104952. https:\/\/doi.org\/10.1016\/j.msard.2023.10495229","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"3063_CR27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/acn3.51732","volume":"10","author":"X Montalban","year":"2023","unstructured":"Montalban X, Matthews PM, Simpson A, Petrie JL, Sammon C, Ramagopalan S, Disanto G, Kuhle G (2023) Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review. Ann Clin Transl Neurol 10(3):302\u2013311. https:\/\/doi.org\/10.1002\/acn3.51732","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"3063_CR28","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Koendgen H, Manfrini M, Belachew S, Stephen L (2020) Hauser SL.Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol 77(9):1132\u20131140. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1568","journal-title":"JAMA Neurol"},{"issue":"4","key":"3063_CR29","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3390\/jcm10040868","volume":"10","author":"K Kapica-Topczewska","year":"2021","unstructured":"Kapica-Topczewska K, Collin F, Tarasiuk J, Czarnowska A, Chor\u0105\u017cy M, Miro\u0144czuk A, Kochanowicz J, Ku\u0142akowska A (2021) Assessment of Disability Progression Independent of Relapse and Brain MR Activity in Patients with Multiple Sclerosis in Poland. J Clin Med 10(4):868. https:\/\/doi.org\/10.3390\/jcm10040868","journal-title":"J Clin Med"},{"issue":"11\u201312","key":"3063_CR30","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1177\/13524585241256540","volume":"30","author":"TA Fuchs","year":"2024","unstructured":"Fuchs TA, Schoonheim MM, Zivadinov R, Dwyer MG, Colato E, Weinstock Z et al (2024) Cognitive progression independent of relapse in multiple sclerosis. Mult Scler 30(11\u201312):1468\u20131478. https:\/\/doi.org\/10.1177\/13524585241256540","journal-title":"Mult Scler"},{"issue":"9","key":"3063_CR31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/14740338.2020.1796969","volume":"19","author":"HS Ng","year":"2020","unstructured":"Ng HS, Rosenbult CL, Tremlett H (2020) Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opin Drug Saf 19(9):1069\u20131094. https:\/\/doi.org\/10.1080\/14740338.2020.1796969","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"3063_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s13760-023-02334-1","volume":"124","author":"S Todorovi\u0107","year":"2024","unstructured":"Todorovi\u0107 S, Vojinovi\u0107 S, Savi\u0107 D, Aleksi\u0107 D, Danilovi\u0107 M (2024) Potential beneficial effect of IFN-\u03b21a and ocrelizumab in people with MS during the COVID-19 pandemic. Acta Neurol Belg 124(2):447\u2013455. https:\/\/doi.org\/10.1007\/s13760-023-02334-1","journal-title":"Acta Neurol Belg"},{"issue":"2","key":"3063_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40120-024-00506-6","volume":"13","author":"MS Freedman","year":"2024","unstructured":"Freedman MS, Coyle PK, Hellwig K, Singer B, Wynn D, Weinstock-Guttman B et al (2024) Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives. Neurol Ther 13(2):283\u2013322. https:\/\/doi.org\/10.1007\/s40120-024-00506-6","journal-title":"Neurol Ther"},{"issue":"5","key":"3063_CR34","doi-asserted-by":"publisher","first-page":"639","DOI":"10.18553\/jmcp.2021.20413","volume":"27","author":"NJ Engmann","year":"2021","unstructured":"Engmann NJ, Sheinson D, Bawa K, Ng CD, Pardo G (2021) Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. J Manag Care Spec Pharm 27(5):639\u2013649. https:\/\/doi.org\/10.18553\/jmcp.2021.20413","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"3063_CR35","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s40120-025-00762-6","volume":"14","author":"S Braune","year":"2025","unstructured":"Braune S, Dirks P, Colloud S, Wang Q, Davies E, Heer Y et al (2025) NeuroTransData Study Group. Persistence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis: Results from the German NeuroTransData Registry. Neurol Ther 14(4):1695\u20131704. https:\/\/doi.org\/10.1007\/s40120-025-00762-6","journal-title":"Neurol Ther"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03063-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03063-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03063-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T13:38:00Z","timestamp":1786455480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-026-03063-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3063"],"URL":"https:\/\/doi.org\/10.1007\/s13760-026-03063-3","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}